3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
101
Lung Neoplasms
41
Neoplasms
13
Neoplasm Metastasis
11
Colorectal Neoplasms
8
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Pancreatic Neoplasms
5
Mesothelioma, Malignant
5
Mesothelioma
5
Carcinoma
5
Meningeal Carcinomatosis
4
Melanoma
4
Colonic Neoplasms
4
Advanced Solid Tumors
4
Rectal Neoplasms
3
Ovarian Neoplasms
3
Lung Diseases
3
Carcinoma, Bronchogenic
3
Adenocarcinoma
3
Uterine Cervical Neoplasms
2
Thoracic Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Respiratory Tract Neoplasms
2
Respiratory Tract Diseases
2
Non-squamous Non-small Cell Lung Cancer
2
Non-Squamous Non-small Cell Lung Cancer
2
Non-Small Cell Lung Cancer Metastatic
2
Non Small Cell Lung Carcinoma NSCLC
2
Neoplasms by Site
2
Interventions
pembrolizumab
1
Pemetrexed
1
Control Groups
1
Cisplatin
1
Carboplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Processes
×
Pemetrexed
×
90 days
×
Clear all
NCT06119581
2026-05-19
SUNRAY-01
Eli Lilly and Company
Phase 3
Recruiting
1,264 enrolled